Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | HTR2C | P28335 | 3/20 | 0.55 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.43 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21671855 | 0.81 | HTR2A (0.46) | HTR2AHTR2CSIGMAR1 | |
| SCHEMBL4049250 | 0.78 | HTR2A (0.59) | HTR2AHTR2CSIGMAR1 | |
| SCHEMBL21278135 | 0.78 | HTR2A (0.73) | HTR2AHTR2CSIGMAR1 | |
| SCHEMBL23725782 | 0.76 | HTR2A (0.50) | HTR2AHTR2CMMP14ADAMTS5SIGMAR1 | |
| SCHEMBL22742673 | 0.75 | SIGMAR1 (0.43) | HTR2AHTR2CSIGMAR1 | |
| SCHEMBL18527235 | 0.72 | HTR2A (0.56) | HTR2AHTR2C | |
| SCHEMBL23726934 | 0.72 | NR1H2 (0.51) | HTR2AHTR2CMMP14ADAMTS5SIGMAR1 | |
| SCHEMBL17809479 | 0.72 | GRM2 (0.49) | MMP14ADAMTS5HTR3AHRH4 | |
| SCHEMBL26683570 | 0.71 | HTR2A (0.46) | HTR2AHTR2CSIGMAR1HRH4 | |
| SCHEMBL5917499 | 0.71 | HTR2C (1.00) | HTR2AHTR2CSIGMAR1HTR3AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744155-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | UNIVERSITETET I OSLO (NO) | 2020-08-18 | — | — | US | disclosed |
| US-20190282606-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | UNIVERSITETET I OSLO (NO) | 2019-09-19 | — | — | US | disclosed |
| US-10322143-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | UNIVERSITETET I OSLO (NO) | 2019-06-18 | — | — | US | disclosed |
| US-20160158271-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | UNIVERSITETET I OSLO (NO) | 2016-06-09 | — | — | US | disclosed |
| US-20160158271-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | UNIVERSITETET I OSLO (NO) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322143-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | ADAMTS5, ADAMTS4, ADAMTS1 | HTR2A 2822/4885HTR2C 2807/4885MMP14 17/4885 |
| US-20190282606-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | ADAMTS5, ADAMTS4, ADAMTS1 | HTR2A 2822/4885HTR2C 2807/4885MMP14 17/4885 |
| US-20160158271-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | ADAMTS5, ADAMTS4, ADAMTS1 | HTR2A 2822/4885HTR2C 2807/4885MMP14 17/4885 |
| US-10744155-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | ADAMTS5, ADAMTS4, ADAMTS1 | HTR2A 2822/4885HTR2C 2807/4885MMP14 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.